30 results on '"Bratland, Åse"'
Search Results
2. High-dose loco-regional pattern of failure after primary radiotherapy in p16 positive and negative head and neck squamous cell carcinoma – A DAHANCA 19 study
3. Tumor volume and cancer stem cell expression as prognostic markers for high-dose loco-regional failure in head and neck squamous cell carcinoma – A DAHANCA 19 study
4. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048
5. Current aspects of the quality of head and neck cancer care – survey of the Scandinavian Society for Head and Neck Oncology.
6. Diagnosis of locally recurrent head and neck squamous cell carcinoma in the Nordic HNC centers and feasibility of the Odense-Birmingham definition
7. 483: Clinical outcomes after dose painting of head and neck cancer with poor prognosis
8. Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
9. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
10. KEYNOTE-630: Phase 3 Study of Adjuvant Pembrolizumab in High-Risk Locally Advanced (LA) Cutaneous Squamous Cell Carcinoma (cSCC)
11. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
12. Head and neck cancer management in the Nordic countries: an effort to harmonize treatment
13. Merkel cell carcinoma
14. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol
15. Abstract CT006: Phase 2 study of pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): KEYNOTE-629
16. KEYNOTE-629: Health-related quality of life (HRQoL) with pembrolizumab (pembro) in patients (pts) with locally advanced (LA) or recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC).
17. Merkelcellekarsinom.
18. The Role of Adjuvant Treatment in Craniofacial Malignancy: A Critical Review
19. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
20. Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis
21. Ongoing and future clinical trials in particle therapy in the Nordic countries
22. Pembrolizumab (P) or P + chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state.
23. KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
24. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
25. Squamous Cell Carcinoma of the Paranasal Sinuses: A Single Center Experience
26. Treatment of Sinonasal Adenocarcinoma: A Population-Based Prospective Cohort Study
27. Squamous Cell Carcinoma of the Paranasal Sinuses: A Single Center Experience.
28. Treatment of Sinonasal Adenocarcinoma: A Population-Based Prospective Cohort Study.
29. Abstract CT321: Prevention of cardiac dysfunction during adjuvant breast cancer therapy: the PRADA study
30. The Role of Adjuvant Treatment in Craniofacial Malignancy: A Critical Review.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.